The biopharmaceutical industry in New York plays a vital role in advancing healthcare through biotechnology and pharmaceuticals. This sector includes companies focused on drug development, therapeutic solutions, and innovative clinical applications, addressing conditions like cancer, infectious diseases, and chronic illnesses. With a surge in research funding and a robust talent pool, many biopharmaceutical firms leverage cutting-edge technology to create groundbreaking therapies. The industry's prospects look bright as collaborations grow between pharmaceutical giants and innovative startups, enabling faster drug discovery and improved patient outcomes in an increasingly competitive market.

The companies featured in this listing vary in size, with many operating from New York City. Founded between 2003 and 2024, these firms specialize in oncology, immunotherapy, and genetic therapies. Ranging from small teams to larger workforce structures, their collaborative efforts reflect systemic innovation in the biopharmaceutical sector. Companies like Menarini Stemline and Cambrian Bio exemplify the intense focus on transformative healthcare solutions that characterize New York's thriving biopharmaceutical scene.

Read on for insights into the top biopharmaceutical companies in New York.

Top 22 Biopharmaceutical Companies Companies in New York

1. Ichnos Sciences

• Website: ichnossciences.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: ichnos-sciences

Ichnos Sciences, also known as Ichnos Glenmark Innovation, is a biotechnology and pharmaceutical company based in New York, USA. Founded in 2019, the company is dedicated to developing innovative therapy solutions specifically targeting hematological malignancies and solid tumors. Ichnos Sciences collaborates with healthcare professionals and organizations to enhance treatment options, aiming to improve patient outcomes in oncology. The company operates three state-of-the-art centers of innovation located in the USA, Switzerland, and India, focusing on clinical development and early discovery research. Their pipeline includes several promising candidates currently in Phase 1 clinical trials, such as ISB 1442 and ISB 2001, which target specific cancer markers. This focus on cutting-edge therapies positions Ichnos Sciences as a significant player in the biopharmaceutical industry, particularly in the oncology sector.

2. Cambrian Bio

• Website: cambrianbio.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: July 2023
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: cambrianbio

Cambrian Bio is a biotechnology firm based in New York, founded in 2019. The company is dedicated to developing innovative therapeutics that target chronic diseases and age-related conditions. Cambrian collaborates with scientists to advance drug development, focusing on extending healthspan—the period of life spent in good health. Their approach combines scientific expertise with a commitment to making transformative therapies widely available. Cambrian operates as a venture capital-backed entity, employing a team of 27 professionals who work on various projects aimed at addressing the biological mechanisms of aging. They are currently involved in clinical trials, including a Phase 1B trial through their subsidiary, Amplifier Therapeutics, which highlights their active role in the biopharmaceutical industry. Cambrian's mission is to create effective treatments that not only address existing health issues but also prevent them, reflecting a modern shift in healthcare towards proactive management of health.

3. Stablix, Inc.

• Website: stablix.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $63.0M, June 2021
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: stablix

Stablix, Inc. is a biotechnology company based in New York City and Boston, specializing in targeted protein stabilization and deubiquitination therapeutics. Founded in 2021, the company is dedicated to developing innovative small-molecule medicines aimed at restoring protein function for various diseases, including cancer and rare disorders. Their RESTORED™ platform utilizes advanced scientific methods to create therapeutic solutions that leverage the body's own cellular mechanisms. Stablix has attracted significant investment, securing $63 million in a Series A funding round led by Versant Ventures, with participation from other notable investors. This funding supports their mission to advance their lead programs toward clinical studies and to establish a strong presence in the biopharmaceutical sector. Stablix was also recognized as one of FierceBiotech's "Fierce 15" companies in 2021, highlighting its potential in the industry.

4. Itb-med

• Website: itb-med.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Sweden 53%, United States (USA) 47%
• Latest funding: $67.0M, April 2018
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: itbmed-ab

ITB-MED is a biotechnology firm based in New York, founded in 2016. The company is dedicated to developing innovative therapies for transplantation and autoimmune diseases. Their primary focus is on TCD601, a proprietary monoclonal antibody that is currently in various phases of clinical trials. ITB-MED aims to enhance patient outcomes by potentially allowing transplant patients to live without the need for immunosuppressive medications. The company has a global reach, conducting clinical trials primarily in the United States and the European Union. With a workforce of around 55 employees, ITB-MED is actively expanding its research efforts and has secured $67 million in funding to support its initiatives. Their commitment to improving the quality of life for patients positions them as a notable player in the biopharmaceutical industry.

5. Sanavia Oncology Inc.

• Website: sanavia.bio
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: sanavia-oncology

Sanavia Oncology Inc. is a New York-based biotechnology firm established in 2020, dedicated to the development of innovative immunotherapies to combat drug-resistant cancer. The company aims to improve patient outcomes by leveraging advanced scientific research and cutting-edge technology. Their team consists of drug developers with backgrounds from renowned institutions such as Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine, and Columbia University. Sanavia's mission is to address the significant challenge of drug resistance in cancer therapies, which affects a large number of patients. They employ a proprietary discovery platform that utilizes high throughput sequencing, advanced microscopy, and artificial intelligence to identify and validate cancer-specific targets. This approach allows them to create antibodies with high specificity for drug-resistant tumors, showcasing their commitment to innovation in oncology. Sanavia actively seeks partnerships with researchers and healthcare organizations to further their mission and drive advancements in cancer treatment.

6. Kallyope

• Website: kallyope.com
• Ownership type: Private Equity
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $8.2M, May 2023
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: kallyope

Kallyope is a biopharmaceutical company based in New York City, founded in 2015. The company is dedicated to discovering and developing novel oral therapeutics that target significant health challenges, particularly in the areas of metabolic, neurological, and gastrointestinal diseases. Kallyope operates through its proprietary Klarity™ platform, which combines various technologies to enhance drug discovery and development processes. Their current pipeline includes programs aimed at treating obesity, type 2 diabetes, and neurological disorders such as migraines. Kallyope has received funding, including an $8.2 million grant in May 2023, to support their research efforts. The company is staffed by a team of experienced scientists and drug developers, many of whom have backgrounds in top institutions and pharmaceutical companies. This expertise underpins their innovative approach to addressing unmet medical needs in the biopharmaceutical sector.

7. OnCusp Therapeutics

• Website: oncusptx.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 50%, China 50%
• Latest funding: Series A, $100.0M, January 2024
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: oncusp-therapeutics

OnCusp Therapeutics is a biotechnology firm based in New York, established in 2021. The company is dedicated to developing innovative cancer treatments by leveraging its expertise in clinical development and a robust industry network. OnCusp focuses on transforming promising research assets into effective therapies for cancer patients. Their primary customers include pharmaceutical companies and biotechnology firms looking to advance their oncology research. Recently, OnCusp raised $100 million in a Series A funding round, which will support the advancement of their pipeline, including CUSP06, an antibody-drug conjugate targeting solid tumors. The company operates with a global perspective, with a workforce split between the United States and China, and is actively engaged in clinical trials to validate their treatment candidates.

8. Menarini Stemline

• Website: stemline.com
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 59%, Italy 10%, Germany 5%, Other 26%
• Latest funding: $677.0M, May 2020
• Founded year: 2003
• Headcount: 501-1000
• LinkedIn: stemline-therapeutics-inc-

Menarini Stemline, a part of the Menarini Group, is a biopharmaceutical company based in New York City, established in 2003. The company specializes in the development and commercialization of innovative oncology therapeutics. Their flagship products include ELZONRIS (tagraxofusp-erzs), which is approved for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), and ORSERDU (elacestrant), aimed at treating advanced breast cancer. Menarini Stemline is actively involved in clinical trials and research, with a pipeline that includes therapies for various hematological malignancies and solid tumors. The company is dedicated to improving patient outcomes and addressing significant gaps in cancer treatment, showcasing their commitment to advancing the field of oncology.

9. Paratus Sciences

• Website: paratussciences.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 70%, Singapore 30%
• Latest funding: Series A, $100.0M, February 2023
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: paratus-sciences

Paratus Sciences, founded in 2021 and based in New York, is a biotechnology firm dedicated to translating the unique biological traits of bats into innovative therapeutics for human health. The company focuses on addressing significant health challenges, particularly in immunological and inflammatory diseases, as well as cardiometabolic disorders. By harnessing the evolutionary advantages of bats, such as their ability to manage inflammation and thrive on high-sugar diets, Paratus aims to discover and develop new treatment options. Their recent Series A funding round raised $100 million in February 2023, reflecting strong investor interest in their research and development efforts. Paratus collaborates with pharmaceutical companies and research institutions, enhancing their capabilities in drug discovery and therapeutic innovation. With a team of experts from prestigious institutions, they are positioned to make meaningful contributions to the biopharmaceutical industry.

10. Igi

• Website: iginnovate.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Switzerland 75%, United States (USA) 16%, India 9%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: ichnos-sciences

Ichnos Glenmark Innovation (IGI) is a biotechnology firm based in New York, New York, that specializes in creating innovative therapies for cancer treatment. Founded in 2019, IGI is dedicated to addressing the challenges posed by hematological malignancies and solid tumors. The company operates with a strong emphasis on research and development, leveraging a proprietary protein engineering platform to create multispecific antibodies. Their pipeline includes several promising candidates currently in Phase 1 trials, such as ISB 1442 and ISB 2001, which target specific cancer markers. IGI collaborates with various stakeholders in the healthcare sector, including partnerships with research institutions and pharmaceutical companies, to enhance their therapeutic offerings. With a workforce of approximately 156 employees, IGI maintains a global presence with centers of innovation in the USA, Switzerland, and India, reflecting their commitment to advancing cancer therapies on an international scale.

11. HiberCell

• Website: hibercell.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $67.4M, May 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: hibercell

HiberCell is a biotechnology firm based in New York, founded in 2019. The company is dedicated to developing innovative cancer therapies that specifically target treatment resistance and metastasis. HiberCell's pipeline includes clinical-stage therapeutic candidates such as HC-7366, which activates the GCN2 kinase, HC-5404, which inhibits the PERK kinase, and Odetiglucan, an immune modulator. These candidates are designed to exploit stress-driven vulnerabilities in cancer cells, aiming to improve patient outcomes in various malignancies. HiberCell has garnered significant financial backing, raising $67.4 million in a Series B funding round in May 2021. This funding supports their ongoing clinical trials and research efforts, positioning them as a relevant player in the biopharmaceutical industry.

12. Seed Therapeutics

• Website: seedtherapeutics.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $24.0M, August 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: seed-therapeutics

Seed Therapeutics is a biotechnology firm based in New York, specializing in drug discovery and development. Established in 2019, the company is dedicated to creating innovative therapies using molecular glues and targeted protein degradation techniques. These methods aim to tackle disease-causing proteins that have traditionally been considered difficult to target. Seed Therapeutics collaborates with prominent pharmaceutical companies, including Eli Lilly and Eisai, to develop treatments for severe diseases, particularly in oncology and neurodegeneration. The company has recently secured $24 million in Series A funding, which underscores its potential and the interest it has garnered in the biopharmaceutical industry. With a focused mission to address significant unmet medical needs, Seed Therapeutics is building a promising pipeline of drug candidates.

13. Codagenix Inc.

• Website: codagenix.com
• Ownership type: Venture Capital
• Headquarters: Farmingdale, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $5.9M, October 2023
• Founded year: 2011
• Headcount: 11-50
• LinkedIn: codagenix

Codagenix Inc., founded in 2011 and based in Farmingdale, New York, is a biotechnology firm dedicated to the development of vaccines and viral therapeutics targeting infectious diseases and cancer. The company utilizes a synthetic biology-driven platform that allows for the precise engineering of viral genomes, resulting in live-attenuated vaccines that promise enhanced safety and efficacy. Codagenix is currently advancing several candidates through its pipeline, including an intranasal COVID-19 vaccine, CoviLiv, which aims to provide broad immunity and can be stored under standard refrigeration. Their work extends beyond human health, as they are also developing solutions for animal health, addressing the need for effective vaccines in livestock and companion animals. Recently, Codagenix secured $5.88 million in funding, reflecting investor confidence in their innovative approach and potential impact on global health.

14. Inspirna, Inc.

• Website: inspirna.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, $55.1M, July 2022
• Founded year: 2010
• Headcount: 11-50
• LinkedIn: rgenix

Inspirna, Inc. is a clinical-stage biopharmaceutical company based in New York, founded in 2010. The company is dedicated to developing innovative cancer therapeutics aimed at addressing previously untreatable cancers. Utilizing their proprietary RNA-DRIVEr™ platform, Inspirna identifies new cancer drivers and develops targeted treatments. Their pipeline includes promising candidates such as Ompenaclid (RGX-202), which is in Phase 2 development for RAS mutant colorectal cancer, and Abequolixron (RGX-104), currently in Phase 1b/2 for non-small cell lung cancer and endometrial cancer. Inspirna's focus on small molecules and biologics aims to provide effective treatment options that enhance patient quality of life. The company has also secured significant funding, with a Series D round raising approximately $55 million in July 2022, indicating strong investor interest in their innovative approach to cancer therapy.

15. ImmunoBrain

• Website: immunobrain.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Israel 89%, France 11%
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: immunobrain-checkpoint

ImmunoBrain is a clinical-stage biopharmaceutical company based in New York, founded in 2015. The company is dedicated to developing novel immunotherapies aimed at treating neurological disorders, with a particular emphasis on Alzheimer's disease. Their flagship product, the IBC-Ab002 antibody, is designed to utilize the immune system's checkpoint pathways to combat neurodegeneration. ImmunoBrain is currently conducting the IBC-01-01 clinical trial, which is a randomized, double-blind, placebo-controlled study targeting early Alzheimer's patients. The company collaborates closely with the Weizmann Institute of Science, where foundational research on the role of the immune system in brain health was pioneered. ImmunoBrain's innovative approach and commitment to addressing critical neurological conditions position it as a noteworthy player in the biopharmaceutical sector.

16. Remix Therapeutics

• Website: remixtx.com
• Ownership type: Venture Capital
• Headquarters: Watertown, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $60.0M, January 2024
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: remix-therapeutics

Remix Therapeutics, founded in 2018 and based in Watertown, New York, is a biotechnology company dedicated to developing innovative small molecule therapies that modulate RNA processing. The company aims to address significant medical needs, particularly in the fields of cancer and neurodegenerative diseases. Remix has established a proprietary drug discovery platform known as REMaster™, which is designed to identify and develop small molecules that can effectively control gene expression and protein production. This platform has enabled the company to generate multiple drug discovery programs that are advancing toward clinical trials. As of May 2024, Remix is conducting Phase 1 clinical trials for its lead candidate, REM-422, which has received Orphan Drug Designation from the FDA for the treatment of adenoid cystic carcinoma and acute myeloid leukemia. The company has also secured substantial funding, with a recent investment of $60 million in January 2024, reflecting strong investor confidence in its potential to deliver new therapeutic options.

17. Aethon Therapeutics

• Website: aethontx.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $30.0M, January 2023
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: aethon-therapeutics

Aethon Therapeutics, based in New York, is a biotechnology firm dedicated to advancing cancer treatment. Founded in 2022, the company specializes in engineering novel antibodies and developing targeted therapies aimed at overcoming drug resistance in cancer cells. Their proprietary HapImmune™ platform is designed to enhance the immune system's ability to identify and attack tumors, particularly those that have evaded detection. Aethon’s innovative approach integrates immunotherapy with targeted covalent inhibitors, creating a synergistic effect that aims to improve treatment outcomes. The company has recently raised $30 million in Series A funding, which underscores its potential and the interest it has generated within the investment community. Aethon Therapeutics is positioned to make a significant impact in the oncology space, catering to healthcare providers and pharmaceutical companies seeking advanced therapeutic options.

18. VivaMed BioPharma

• Website: vivamed.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2003
• Headcount: 11-50
• LinkedIn: vivamed-inc

VivaMed BioPharma, founded in 2003 and based in New York, specializes in the development of therapeutics for chronic conditions that resist conventional treatments. The company collaborates with medical research universities and other organizations to transition drug assets from late preclinical stages to clinical proof of concept. Their focus areas include central nervous system disorders, rare diseases, metabolic issues, and cardiopulmonary conditions. With a portfolio of over 50 drug assets, one-third of which are currently in clinical development, VivaMed plays a crucial role in advancing innovative therapies. They exit their projects at successful Phase II trials, partnering with larger pharmaceutical companies for the subsequent Phase III trials necessary for regulatory approval. This strategic model highlights their commitment to bridging research and commercialization in the biopharmaceutical field.

19. Sapience Therapeutics, Inc.

• Website: sapiencetherapeutics.com
• Ownership type: Venture Capital
• Headquarters: Tarrytown, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $2.0M, May 2023
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: sapience-therapeutics-inc-

Sapience Therapeutics, Inc., founded in 2015 and based in Tarrytown, New York, is a biotechnology firm dedicated to developing peptide-based cancer therapies. The company specializes in creating innovative treatments targeting high mortality cancers through its proprietary SPEARs™ technology. This technology allows for the design of peptide antagonists that can disrupt oncogenic and immune-modulating pathways. Currently, Sapience is advancing its clinical pipeline, which includes ST101, a first-in-class C/EBPβ antagonist, and ST316, a β-catenin antagonist. Both candidates are undergoing Phase 2 clinical trials, demonstrating the company's active role in the oncology therapeutic landscape. In May 2023, Sapience received a $2 million grant to further evaluate ST316, highlighting their ongoing efforts to secure funding for research and development. Their focus on addressing significant challenges in cancer treatment positions them as a noteworthy player in the biopharmaceutical industry.

20. Ichor Biologics

• Website: ichorbiologics.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: India 95%, United States (USA) 5%
• Founded year: 2014
• Headcount: 1-10
• LinkedIn: ichor-biologics

Ichor Biologics is a New York-based biotechnology firm founded in 2014, specializing in the development of antibody-based therapeutics aimed at combating infectious diseases. The company has created a novel platform that isolates naturally occurring human monoclonal antibodies, which are crucial for developing effective treatments against various pathogens. Ichor's team consists of skilled scientists with expertise in immunology and infectious diseases, working to accelerate the therapeutic development process. Their research has led to promising results, including the protection of animals against lethal hantavirus infections, showcasing the potential of their antibody-based drugs. Ichor has also secured funding from the National Institutes of Health to further its work in this area, indicating recognition of its innovative approach and the importance of its mission. The company aims to leverage its technology to establish partnerships and licensing deals, thereby contributing to the broader biopharmaceutical landscape.

21. Creative Biolabs

• Website: creative-biolabs.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn: creative-biolabs

Creative Biolabs, founded in 2005 and based in New York, is a private biotechnology service provider that specializes in custom antibody discovery, engineering, and manufacturing solutions. The company caters to researchers and pharmaceutical firms, offering a comprehensive range of services designed to advance drug development and therapeutic applications. Their expertise includes various technologies such as phage display, yeast display, and hybridoma methods for antibody discovery. Creative Biolabs is committed to delivering high-quality, tailored solutions that meet the specific needs of their clients. They have established a reputation for reliability and innovation in the biotechnology sector, contributing to numerous projects that enhance the efficacy of therapeutic antibodies. With a workforce of 51-200 employees, the company operates entirely within the United States, focusing on providing specialized services that support the biopharmaceutical industry.

22. United Biomedical, Inc. (UBI)

• Website: unitedbiomedical.com
• Ownership type: Private
• Headquarters: Hauppauge, New York, United States (USA)
• Employee distribution: Taiwan 60%, United States (USA) 40%
• Founded year: 1985
• Headcount: 11-50
• LinkedIn: united-biomedical-inc.-ubi-

United Biomedical, Inc. (UBI), founded in 1985 and based in Hauppauge, New York, is a private biopharmaceutical company dedicated to the development of diagnostics and immunotherapeutics. With a workforce of approximately 45 employees, UBI operates primarily in the human and animal health sectors. The company has made significant strides in the industry, being recognized for its pioneering work in peptide-based technologies. UBI has developed a range of products, including vaccines and specialty injectables, aimed at improving health outcomes. Their product pipeline addresses various therapeutic areas, such as neurology, immunology, and infectious diseases. UBI has a multinational presence, with a significant portion of its operations in Taiwan, and has partnered with global firms for the commercialization of its innovations. Their commitment to scientific advancement is evident in their history of successful product development and their ongoing research efforts.

Biopharmaceutical Companies Insights: Key Companies in New York

Want to Find More Biopharmaceutical Companies Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!